Subscribe
helsinki-aippi-harbour
30 September 2013Big Pharma

AIPPI 2013: Pharmaceutical products and the trademark hiccup

During a workshop on September 6, one issue discussed was the difference between a trademark signifying a branded product and an international nonproprietary name (INN), which signifies a medical effect.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk




Editor's picks

‘We created law’: G1/24 and the creation of the ‘diamond standard’
Europe
‘We created law’: G1/24 and the creation of the ‘diamond standard’
3 July 2025

Editor's picks

Europe
‘We created law’: G1/24 and the creation of the ‘diamond standard’
3 July 2025
Americas
A step too far? Why Stewart’s approach is dividing opinion
24 June 2025
Europe
Diverging in the detail: UPC local divisions and Court of Appeal take different paths
19 June 2025
Europe
UPC confirms permanent injunction against Curio in 10x tech dispute
17 June 2025
Americas
LSPN: In-house ‘chess game’ is the same, but the rules have changed
9 May 2025
Americas
Life sciences leaders recognised at LSPN Awards USA 2025
8 May 2025

More features

Lord Justice Birss to become chancellor of the High Court
Sanofi successfully challenges rare disease patent in Europe
Bayer appoints new head of IP
WATCH: Policy direction—where are we now?
BMS faces fresh lawsuit over alleged cancer drug monopoly
WATCH: Synergy in science—navigating the landscape of pharmaceutical collaborations
Boies Schiller Flexner adds three-strong litigation team
AstraZeneca forced to clarify deal terms in row with university